Abstract
The antisense oligonucleotide aprinocarsen specifically inhibits the transcription of protein kinase C-alpha. This study evaluated the response rate of the combination therapy of aprinocarsen, gemcitabine, and carboplatin in previously untreated patients with advanced non-small cell lung cancer (NSCLC). Secondary objectives included the measurement of time-to-event efficacy parameters and toxicity. Patients with stage IV or stage IIIB disease (N(3) and/or pleural/pericardial effusion) were treated with gemcitabine 1,250 mg/m(2) on days 1 and 8 and carboplatin AUC 5 on day 1 every 21 days. Aprinocarsen was administered as 2mg/kg/day continuous iv infusion on the first 14 days of each cycle, following the carboplatin treatment. A total of 36 patients received a median of 3 treatment cycles, with 10 patients completing 6 cycles. No complete response was observed, while partial response was seen in 25% of patients. Stable disease and progressive disease was observed in 36.1% and 22.2% of patients. The median overall survival was 8.3 months, and the median duration of progression-free survival was 5.7 months (95% CI, 3.2-7.1 months). Thrombocytopenia (78%) and neutropenia (50%) were the major grade 3/4 toxicities. Enrollment for thi...Continue Reading
References
Aug 25, 1988·Nature·Y Nishizuka
Sep 1, 1993·Pharmacology & Therapeutics·A Basu
Feb 3, 2000·Journal of the National Cancer Institute·P TherasseS G Gwyther
Oct 19, 2000·Cancer Investigation·B P MoniaF A Dorr
Aug 22, 2001·Lancet·I TammG Hartmann
Jun 12, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Alexandru C GrigorescuEmil Corlan
Jun 27, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Paola MazzantiTullio Battelli
Jul 25, 2003·Cancer·Sarah DansonNicholas Thatcher
Aug 21, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Petr ZatloukalMilan Kůta
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U GatzemeierV Hirsh
Jan 13, 2004·Cancer·Ranjana AdvaniBranimir I Sikic
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin J EdelmanDavid R Gandara
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S RaoJ T Holmlund
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miguel A Villalona-CaleroJon Holmlund
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M RuddS M Lee
Citations
Jun 23, 2007·Nature Reviews. Cancer·Helen J Mackay, Christopher J Twelves
Jan 27, 2009·Cardiovascular Research·Suresh Selvaraj PalaniyandiDaria Mochly-Rosen
Aug 15, 2014·The American Journal of Surgical Pathology·Claudio AgostinelliTeresa Marafioti
Nov 8, 2011·Clinics in Chest Medicine·Anil VachaniSteven M Albelda
Nov 12, 2009·European Journal of Pharmacology·Yoshiki TatsudaKazuyuki Hirano
Jan 25, 2008·Proteins·Sishi TangLakshmi P Kotra
Apr 3, 2008·The Journal of Pharmacy and Pharmacology·Crispin R Dass, Peter F M Choong
Jan 3, 2013·The Journal of Gene Medicine·Mostafa SaffariHamid Reza Moghimi
Aug 19, 2015·Biochemical and Biophysical Research Communications·Jin O-UchiCoeli M B Lopes
Mar 19, 2014·International Journal of Cardiology·Dan LuLianfeng Zhang
Oct 30, 2014·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·L L ZhangQ H Zhou
Mar 10, 2015·Cancer Letters·W MiklosP Heffeter
Sep 10, 2016·Cancer Treatment Reviews·Pedro BarataDavid S Hong
Dec 12, 2020·Advances in Biological Regulation·Adrian R Black, Jennifer D Black
Jun 3, 2021·International Journal of Molecular Sciences·Mohammad Mojtaba SadeghiYusuf A Hannun